Syndax Pharmaceuticals (SNDX)
(Delayed Data from NSDQ)
$20.81 USD
-0.12 (-0.57%)
Updated Aug 27, 2024 04:00 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Cash flow Statements
Fiscal Year End for Syndax Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -209.36 | -149.34 | 24.93 | -73.16 | -56.05 |
Depreciation/Amortization & Depletion | -14.79 | -3.35 | 0.69 | -0.04 | -0.33 |
Net Change from Assets/Liabilities | 31.86 | 1.66 | -9.60 | -7.93 | -0.24 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 31.69 | 17.36 | 13.12 | 9.87 | 6.01 |
Net Cash From Operating Activities | -160.60 | -133.68 | 29.13 | -71.26 | -50.61 |
Property & Equipment | 0.00 | 0.23 | -0.13 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 117.61 | -186.41 | -40.74 | -142.53 | 12.78 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 117.61 | -186.19 | -40.87 | -142.53 | 12.78 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 264.13 | 193.25 | 117.89 | 284.69 | 28.57 |
Issuance (Repayment) of Debt | 0.00 | -21.00 | 0.58 | 19.73 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 264.13 | 172.25 | 118.46 | 304.42 | 28.57 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 221.14 | -147.61 | 106.72 | 90.63 | -9.26 |
Cash at Beginning of Period | 74.47 | 222.08 | 115.36 | 24.72 | 33.99 |
Cash at End of Period | 295.61 | 74.47 | 222.08 | 115.36 | 24.72 |
Diluted Net EPS | -2.98 | -2.46 | 0.46 | -1.87 | -1.84 |
Fiscal Year End for Syndax Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -140.46 | -72.40 | -209.36 | -136.89 | -85.74 |
Depreciation/Amortization & Depletion | -7.46 | -3.82 | -14.79 | -11.34 | -7.68 |
Net Change from Assets/Liabilities | -26.55 | -16.47 | 31.86 | 5.85 | 4.26 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 19.28 | 9.14 | 31.69 | 23.12 | 14.56 |
Net Cash From Operating Activities | -155.19 | -83.55 | -160.60 | -119.25 | -74.60 |
Property & Equipment | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -37.65 | -99.40 | 117.61 | 133.90 | 93.82 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -37.65 | -99.40 | 117.61 | 133.90 | 93.82 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 2.84 | 2.17 | 264.13 | 5.65 | 3.80 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 2.84 | 2.17 | 264.13 | 5.65 | 3.80 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -190.00 | -180.78 | 221.14 | 20.30 | 23.02 |
Cash at Beginning of Period | 295.61 | 295.61 | 74.47 | 74.47 | 74.47 |
Cash at End of Period | 105.61 | 114.83 | 295.61 | 94.77 | 97.49 |
Diluted Net EPS | -0.80 | -0.85 | -1.02 | -0.73 | -0.64 |